Bill seeks exclusivity for added orphan indications
This article was originally published in Scrip
Drug makers with approved medicines on the US market could earn an extra six months of exclusivity protection for their products if the companies are able to show the drugs work to prevent, diagnose or treat a rare disease or condition if Congress adopts a new bill, which was introduced in the House by Representative Gus Bilirakis (Republican-Florida).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.